Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
S TadbiriLaurent Peyrin BirouletM SerreroJ FilippiBenjamin ParienteXavier RoblinAnthony BuissonC StefanescuC Trang-PoissonR AltweggP MarteauT VaysseA BourrierS NanceyD LaharieM AllezG SavoyeC GillettaC GagniereL VuittonS ViennotA AubourgA-L PelletierG BouguenV AbitbolM FumeryP ClaudepierreY BouhnikAurélien Amiotnull nullPublished in: Alimentary pharmacology & therapeutics (2017)
Vedolizumab therapy is commonly associated with improvement in EIM. This was associated with quiescent IBD and recent EIM. However, paradoxical skin manifestation and inflammatory arthralgia/arthritis may occur upon vedolizumab therapy.